Investment Highlights: ■ Raising Price Target – Filing Expected This Year. Early this morning, Trius reported positive data from its second Phase 3 trial of tedizolid phosphate (TR-701), the firm’s lead drug candidate for the treatment of bacterial infections. In…
Month: June 2013
Video Chart Analysis and Commentary on Trius Therapeutics ($TSRX)
Video Chart analysis and commentary on Trius Therapeutics (TSRX). From the Aegis analyst report, we read the following: In the wake of this data, we are raising our probability of success for tedizolid from 60% to 80%, which increases the…